

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

1 **Best Practices for Pain Management in Infants, Children, Adolescents and**
2 **Individuals with Special Health Care Needs**

3

4 **Originating Council**

5 Council on Clinical Affairs

6

7 **Adopted**

8 2018

9

10 **Purpose**

11 The purpose of this document is to provide dental professionals and other stakeholders with current best
12 practices for pain management in pediatric dentistry.

13

14 **Methods**

15 This document was developed by the Council on Clinical Affairs and adopted in 2018. It is based on a
16 review of current dental and medical literature pertaining to pain management in pediatric dental patients.
17 Review of existing Federal and professional pain management guidelines and consensus statements were
18 used to assist with this document. An electronic search was conducted using PubMed® with the terms:
19 dental pain management, pediatric pain assessment, preemptive analgesia, pediatric and acetaminophen,
20 adolescent and acetaminophen, pediatric and NSAIDs, adolescent and NSAIDs, pediatric and opioids,
21 adolescent and opioids, opioid risk, adolescent orofacial pain, pediatric and adolescent chronic pain, non-
22 pharmacologic pain management; fields: all; limits: within the last 10 years, humans, English, and clinical
23 trials. 1395 articles met these criteria. Papers for review were chosen from this list and from references
24 within selected articles. When data did not appear sufficient or were inconclusive, recommendations were
25 based upon expert and/or consensus opinion by experienced researchers and clinicians.

26

27 **Background**

28 Pain is defined by the International Association of the Study of Pain (IASP) as “an unpleasant sensory
29 and emotional experience associated with actual or potential tissue damage or described in terms of such
30 damage.”¹ Pain management includes both pharmacologic and nonpharmacologic strategies to treat both
31 acute and chronic pain, and professional and educational requirements are being reviewed at multiple
32 levels.^{2,3,4,5} This document discusses pain processing, pain assessment, pain categories, pre-emptive

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

33 analgesia, non-pharmacologic pain management, pharmacologic pain management, and best practices for
34 prescribing opioids.

35

36 **Pain processing**

37 Understanding pain processing is essential for the management of pain. Pain experience in childhood may
38 shape future pain experiences in adulthood.⁶ Dental pain is an inflammatory condition resulting from
39 invasive treatment, tissue damage, or infection.⁷ Swelling, hyperthermia, and activation of biochemical
40 cascades are hallmarks of inflammatory pain.^{7,8} Thermal, mechanical, and chemical stimuli activate free
41 nerve endings.^{9,10} Sensory signals travel along afferent trigeminal nerve fibers and relay information to
42 the brainstem and higher structures involved with the perception of pain.¹¹ Under normal conditions the
43 perception of pain persists until the stimulus is removed.

44

45 *Peripheral sensitization*

46 Terminal nerve endings at the site of tissue injury exhibit an enhanced neuronal response.⁹ This local
47 increase in nerve membrane excitability is referred to as peripheral sensitization.¹² The exaggerated
48 response to stimuli in the region of tissue damage is called primary hyperalgesia.¹¹

49

50 *Central sensitization*

51 Central sensitization refers to enhanced functional status of pain circuits and pain processing at the level
52 of the central nervous system (CNS).^{8, 12, 13} Both secondary hyperalgesia, which is an increase in pain
53 intensity to noxious stimuli outside of the area of tissue damage, and allodynia, which refers to pain
54 perception following innocuous stimuli such as light touch, are characteristics of central sensitization.¹³

55

56 *Pain modulation*

57 Modulation of pain pathways occurs through CNS excitatory and inhibitory processes. Ascending
58 facilitating and descending inhibitory processes enhance or suppress the pain experience, respectively.¹²
59 Both pharmacologic and nonpharmacologic methods target these processes to alter pain processing^{14, 15}.

60

61 **Pain assessment**

62 Ethnic, cultural, and language factors may influence expression and assessment of pain.¹⁶ Pain is assessed
63 using self-report, behavioral (vocalization, facial expression, body movement) and biological measures
64 (heart rate, transcutaneous oxygen, sweating, stress response).¹⁷ Direct questioning or a structured,
65 comprehensive pain assessment can be clinically beneficial for pediatric and adolescent patients.^{17,18}

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

66 Conducting a structured interview begins with asking specific questions regarding pain onset, provoking
67 factors, palliative factors, quality or character, region or location, severity or intensity, timing or duration,
68 and impact on daily activities. Obtaining information through self-report can be aided by asking the child
69 to make comparisons, using temporal anchors and facilitating communication through objects or
70 gestures.¹⁷ Assessing behavioral reactions and physiological reactions to pain are required in non-verbal
71 and young patients.¹⁷ Patients 4-12 years old can likely quantify pain based on a series of faces.¹⁹
72 Patients older than seven should be able to mark pain using a Visual Analogue Scale (VAS) or numeric
73 scale.^{19, 20} Validated instruments such as Faces Pain Scale (Revised), Visual Analogue Scale (VAS),
74 numeric rating scale, Faces, Legs, Activity, Cry, and Consolability score (FLACC), Faces, Legs, Activity,
75 Cry and Consolability, and the McGill Pain Questionnaire are available for assessing pain in verbal or
76 nonverbal patients.^{19,21,22}

77

78 **Pain categories**

79 Pain may be divided into diagnostic categories as somatic, visceral and neuropathic.^{23,24,25,26} Pain
80 encountered in dentistry is typically inflammatory and categorized as somatic (i.e. periodontal, alveolar,
81 mucosal) or visceral (i.e. pulpal) pain.²⁷

82

83 Pain may be categorized as acute or chronic. Acute pain that fails to respond to treatment may become
84 chronic over time.²⁸ Chronic pain refers to pain that is dysfunctional and persists beyond the time for
85 typical tissue healing.^{29,30,31,32} Temporomandibular disorder (TMD) is an example of a chronic pain
86 condition encountered in dentistry.³³

87

88 **Pain management**

89 *Pre-emptive pain management*

90 Pre-emptive pain management refers to administration of an anesthetic agent, medication, or technique
91 prior to a surgical event with the goal of decreasing pain. Goals of pre-emptive pain management include:
92 attenuating central sensitization, decreasing postoperative pain, improving recovery, and reducing
93 postoperative analgesic consumption.^{11,15} Postoperative pain management in pediatric patients has been
94 suboptimal in large part because of the misconception that children do not feel pain as severely as adults
95 do³⁴ and the fear of adverse events.³⁵ It has been shown that nearly 50% of patients undergoing dental
96 rehabilitation describe moderate to severe pain³⁶ and there is data to support pre-emptive measures to
97 optimize pain control for a variety of dental and surgical procedures.³⁷ However, level of evidence is low
98 due to sparse well-controlled trials.^{38,39,40}

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

99

100 Achieving profound anesthesia prior to initiating treatment decreases central sensitization³⁷. Topical
101 anesthetics are used in a dentistry to minimize pain; however, these medicaments alone may not be
102 sufficient for dental procedures.^{41,42} Other factors that may contribute to a patient’s pain experience are
103 the anesthetic properties and the needle used during the injection.⁴³ Distraction techniques made at the
104 time of the injection such as jiggling the patient’s cheek take advantage of Aβ fiber signal dominance and
105 can significantly reduce the intensity of pain-related C-fiber signaling.⁴³ Buffering or decreasing acidity
106 of local anesthetic using sodium bicarbonate can decrease injection site pain and postoperative discomfort
107 by increasing the pH of the anesthetic. This is a well-accepted technique in medicine but has not been
108 commonly used in dentistry.^{43,44} Finally, decreasing anesthetic delivery rate has also demonstrated pain
109 reduction during injection.⁴⁵

110

111 In a study by Shivani, the use of pre-emptive analgesics in conjunction with local anesthetics increased
112 the ability to achieve pulpal anesthesia in patients with irreversible pulpitis when compared with
113 placebo.⁴⁶ The pre-emptive analgesics most commonly used in dentistry are nonsteroidal anti-
114 inflammatory drugs (NSAIDS) and acetaminophen either alone or in combination.⁴⁷ Analgesics with
115 sedative properties are often administered during the pre, peri, and postoperative periods when moderate
116 to severe pain is anticipated.^{48,49,50,51}

117

118 *Use of local anesthesia during general anesthesia*

119 Although pain is not experienced during general anesthesia, central sensitization occurs when peripheral
120 nerves are stimulated.^{37,52,53} Operating without local anesthesia may result in “priming” of CNS neurons
121 and increased future pain sensitivity.⁶ Central sensitization is minimized with pre-emptive analgesia or
122 anesthesia. For this reason, regional block or infiltration anesthesia is commonly performed prior to
123 surgical procedures to decrease postoperative pain.^{11,54,55} However, pharmacologic and cardiac
124 considerations along with avoiding the numb sensation and potential for self-inflicted oral trauma are
125 reasons providers may choose not to provide local anesthesia during general anesthesia.^{55,56}

126

127 **Non-pharmacologic approaches to pain management**

128 Studies suggest that nonpharmacologic interventions may be effective alone or as adjuncts to
129 pharmacological interventions in managing procedure related pain, anxiety and distress with minimal risk
130 of adverse effects.^{9,57,58,59} Fear and anxiety activate circuits within the CNS that facilitate pain.²⁹ Creating
131 a safe, friendly environment may help a child feel more comfortable and less stressed.^{58,60} The American

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

132 Academy of Pediatrics and the American Pain Society recommend that providers reduce distress-
133 producing stimulation and provide a calm environment for procedures to improve pain management.³
134 Emotional support is a key component in creating a comfortable environment.⁶¹ Although there is no
135 evidence that the presence of parents decreases pain, there is data to support that it may decrease the
136 child's anxiety and distress.⁶⁰ Conversely, parental catastrophizing has been associated with poor
137 outcomes for pediatric pain management.⁶² The American Academy of Pediatrics and American Pain
138 Society jointly advise expectation management for parents along with preparation for comforting their
139 children when pain is anticipated.³ Individual studies have shown the efficacy of psychologic techniques,
140 including preparation and information, parent coaching or training, suggestion, memory alteration or
141 change, and coping self-statements.^{63,64,65} However, a 2013 Cochrane review concluded that there is no
142 strong evidence available to support the efficacy of preparation and information, combined cognitive or
143 behavioral strategies, parent coaching plus distraction, or suggestion for reducing needle-related pain and
144 distress.⁶⁶

145

146 *Distraction and Imagery*

147 Distraction is an effective method of pain management in the pediatric population.^{16,67} It can be cognitive
148 (counting, nonprocedural talk) or behavioral (videos, games), both of which aim to shift attention away
149 from pain. Distraction techniques such as bubbles, counting, conversation, music, television, toys and
150 video games may be used by health care providers or the child's caregiver.^{58,60} There is strong evidence
151 supporting the efficacy of distraction techniques for needle-related pain and distress in children and
152 adolescents.⁶⁶ Distraction has been shown to be significantly effective when measuring pulse rates,
153 respiratory rates, and self-reported pain.^{3,60} Additionally, distraction intervention has been shown to
154 lower the perception of pain distress in younger children as reported by parents.⁶¹ Distraction techniques
155 may be of great use with patients with special needs that have shortened attention spans and are unable to
156 understand verbal reasoning or reassurance.⁶³

157

158 Imagery guides the child's attention away from the procedure by harnessing imagination and story-telling.
159 Imagery in combination with distraction have been shown to be helpful in decreasing postoperative pain
160 in children.^{67,68} This technique requires the active cooperation of the patient and is most effective when
161 used for children over 8 years old.⁵⁷

162

163 *Hypnosis*

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

164 Hypnotherapy aims to alter sensory experiences and dissociate from pain experiences, and hypnosis is
165 best for school aged or older children.²⁶ There is strong evidence that hypnosis is effective in reducing
166 needle-related pain and distress in children and adolescents.^{66,69} There is no evidence that hypnosis alone
167 is capable of producing an anesthetic effect for dental procedures; therefore, it should always be
168 combined with good local anesthetic techniques.⁶⁹

169
170 *Other Techniques*

171 Studies have shown efficacies for pediatric pain management with other techniques such as relaxation and
172 breathing exercises, transcutaneous electrical nerve stimulation, acupuncture, counterstimulation, virtual
173 reality, and music therapies.^{65, 67,70-75} Additional research is need on these interventions to measure their
174 effectiveness.

175
176 **Pharmacologic Agents**

177 Management of pain in children is changing rapidly as a result of improvements in the appreciation of
178 pediatric pain and pharmacologic knowledge; however randomized controlled trials are lacking in
179 children so the use of many pain medications are still considered “off label.”^{76,77} The American Academy
180 of Pediatrics consensus statement on the assessment and management of pain in children recommends
181 acetaminophen, ibuprofen and opioids as the top three medication choices for the treatment of acute pain
182 in children.^{3,16}

183
184 **Non-opioid analgesics**

185 *Nonsteroidal anti-inflammatory drugs (NSAIDS):*

186 NSAIDS are among the most commonly used class of drugs and have anti-inflammatory, analgesic,
187 antipyretic and antiplatelet properties.⁷⁸ They inhibit prostaglandin synthesis; with specific action on
188 cyclooxygenase (COX).⁵⁰ Representatives of the major categories of NSAIDS are: Salicylic acids:
189 aspirin; Acetic acids: Toradol; Propionic acids: ibuprofen, naproxen; and Cyclooxygenase 2 selective:
190 Celebrex. Ibuprofen in oral or IV form is a commonly used analgesic and antipyretic agent used in
191 pediatrics.⁷⁸ Ketorolac, an IV or intranasal NSAID is useful in treating moderate to severe acute pain in
192 patients unable or unwilling to swallow oral NSAIDS.^{26,54,79} Some of the adverse effects associated with
193 NSAIDS include: inhibition of bone growth and healing, gastritis with pain and bleeding, decreased renal
194 blood flow, inhibition of platelet function, and increased incidence of cardiovascular events.²⁶ A specific
195 concern with NSAIDS is the potential to exacerbate asthma due to a shift in leukotrienes.⁷⁶ Due to shared

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

196 pathways NSAIDS and steroidal anti-inflammatory medications should not routinely be co-
197 administered.⁸¹

198

199 *Acetaminophen (APAP, paracetamol):*

200 Acetaminophen is an analgesic with efficacy for mild to moderate pain and is an antipyretic.⁸¹ Unlike
201 NSAIDS, acetaminophen is centrally-acting and does not have effects on gastric mucosal lining or
202 platelets.⁸¹ The mechanism of action of acetaminophen is the blockade of prostaglandin and substance P
203 production; and is administered in tablets, capsules, liquid but also available as oral disintegrating tablets
204 (ODT) and oral disintegrating films (ODF), rectal and IV forms.⁵⁰ Studies have shown that rectal
205 administration has somewhat higher bioavailability and faster onset than the oral route since it partially
206 bypasses hepatic metabolism.⁸⁰ Pain control can be optimized when acetaminophen and NSAIDs are
207 alternated or staggered which is known as multi-modal therapy.^{76,81,82}

208

209 *Opioid analgesics*

210 Opioid analgesics have been used for many years to produce profound pain relief in all age groups.
211 Opioid analgesics are considered for acute moderate to severe pain refractory to other therapies. Common
212 use in pediatric patients include: cancer pain, sickle cell crises, osteogenesis imperfecta pain,
213 epidermolysis bullosa pain, and pain related to neuromuscular disease.^{83,84,85} Limited studies are available
214 regarding postoperative opioid use in pediatric dentistry, but it is also rare that pediatric dental patients
215 should require opioid analgesics following dental treatment.⁵⁰ Major concerns of opioid analgesics in the
216 pediatric population are: efficacy, safety, misuse, and accidental deaths.^{77,86,87}

217

218 Opioids interact differentially with mu, kappa, and delta receptors in the central nervous system. Opioid
219 agonists act on receptors located in the brain, spinal cord and digestive tract. Pathways of opioid receptor
220 signaling are multiple and include G-protein receptor coupling, cyclic adenosine monophosphate
221 inhibition and calcium channel inhibition.⁵⁰ Activation of opioid receptors can cause respiratory
222 depression, pupil constriction (miosis), euphoria, sedation, physical dependence, endocrine disruption,
223 and suppression of opiate withdrawal.²⁶ Pruritus (itching) may also occur due to histamine release that
224 accompanies some opioid analgesics.⁴⁸ Naloxone is a mu opioid receptor competitive antagonist usually
225 administered parenterally to counter opioid overdose.⁵⁰ If patients are actively prescribed opioids for
226 cancer or non-cancer pain, providers should choose another agent for analgesia or consult with specialty
227 provider regarding opioid dosing.⁷⁷

228

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

229 *Opioids with active metabolites*

230 Codeine, tramadol, and hydrocodone are opioids that are broken down in the liver to active metabolites by
231 highly variable cytochrome enzyme CYP2D6.^{22,81,88} These drugs are ineffective in some children due to
232 poor drug metabolism.⁹ Yet other patients known as “hyper-metabolizers” break these prodrugs to their
233 active forms too quickly potentially resulting in overdose, respiratory depression, and even death.⁸⁸ The
234 FDA and European Medicines Agency (EMA) have issued warnings and contradiction statements over
235 the past few years on codeine and tramadol because of this.^{88,89} Hydrocodone also relies on cytochrome
236 p450 metabolism and has potential for similar adverse effects. Although systematic reviews have
237 demonstrated that these medications might provide appropriate analgesia when compared to placebo,
238 evidence is not convincing and safety concerns exist^{90,91}. In 2017, the FDA issued a warning specifically
239 for codeine and tramadol in all patients less than 12 years of age, stating they are no longer considered
240 safe to use in this age group.⁸⁸ Deaths have occurred in children using these medicines for post
241 tonsillectomy and/or adenoidectomy pain management, general pain, sore or strep throat pain, and cold
242 and cough.⁸⁸ The FDA warns that in the 12-17-year age group, these medications should not be used in
243 high-risk patients (obesity, OSA, lung tissue disease).⁸⁸. Furthermore, tramadol and codeine should not
244 be used if breastfeeding since active metabolites are present in breastmilk.⁸⁸

245

246 *Opioids without active metabolites*

247 Inactive metabolites refer to metabolites that do not have a noticeable effect on the CNS. Naturally-
248 occurring morphine and the synthetics oxycodone and fentanyl do not have CYP2D6 considerations since
249 they do not contain active metabolites.⁸¹. Potency of all opioids is compared to morphine. Morphine
250 provides rapid relief of severe pain for 2-3 hours and is associated with histamine release and respiratory
251 depression. Fentanyl is 100X more potent than morphine, is ultra-short acting, and is used for invasive
252 procedures and sedations.²⁶ Chest wall rigidity is a well-known adverse reaction to fentanyl.²⁶ Rapidly-
253 acting oxycodone has a longer half-life than morphine and is more potent. Oxycodone is available as a
254 single agent or is combined with aspirin, ibuprofen or acetaminophen. It comes in tabs, caps, oral solution
255 and oral concentrate and use is considered off label in children 12 years of age and younger.⁵⁰

256

257 *Opioid concerns and CDC recommendations:*

258 Trends in opioid overdose, opioid misuse, and concerns for opioid addiction prompted the CDC to issue
259 guidelines for prescribing opioids for chronic pain.³⁰ The guideline aims to improve prescribing practices
260 to ultimately benefit patient health and quality of life.⁹³ Although the guidance is specific for adults with
261 chronic pain, all prescribers should be mindful of high-risk prescribing practices.⁸³ The guideline

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

262 recommends limiting opioids for moderate to severe pain, restricting prescription to three days, and
263 providing concurrent pharmacologic and non-pharmacologic therapy.³⁰ The guideline also advises
264 against overlapping benzodiazepines and opioids prescriptions.³⁰ Dentists can have a role in decreasing
265 the overall availability of opioids for nonmedical use and abuse in the home and community.⁹⁵

266
267 Deaths due to opioid overdoses are at record highs prompting the CDC to declare an opioid epidemic in
268 2011.^{87,95} Poisoning deaths of opioids nearly quadrupled from 1999 to 2011 with the most recent data at
269 5.4 per 100,000 individuals. The study also demonstrated a trend towards increased pediatric emergency
270 department (ED) visits due to opioid ingestion and a greater than 5-fold increase in overdose death rates
271 in the 15-24-year age group.⁹⁵ Since commercial opioids are often combined with acetaminophen; the
272 potential for hepatic failure from toxic levels of acetaminophen must also be considered.⁷ As previously
273 stated, providers treating pediatric and adolescent populations should avoid prescribing opioid analgesics
274 when patients are using benzodiazepines.³⁰

275
276 Risky use of opioids among children and adolescents is a growing trend and the concern for opioid use
277 disorder (OUD) in adolescents is significant.^{96,97} In 2016, the American Academy of Pediatrics released a
278 policy statement that recommended timely intervention to curb opioid use disorder with the goal of
279 eliminating long-term medical, psychiatric and social consequences of ongoing substance abuse.⁹⁸

280
281 Risk mitigation begins with understanding how to recognize drug seeking behavior.² To address the
282 potential risk of opioid use/abuse in pediatric patients, the CDC recommends that practitioners use
283 screening tools. Unfortunately, there is no common standard for adolescent patients. Therefore, the
284 practitioner should, at least, perform a thorough review of medical history including analgesics used in
285 the past before prescribing.⁷⁷ It is also known that children of parents that abuse opioids are at an
286 increased risk for neglect and often suffer from parental instability and lack of structure in the home
287 setting.⁹⁹ Therefore, behavioral health support may be required for emotional disturbances such as drug
288 abuse, depression, or PTSD.⁹⁹ Although, screening of parents is recommended by the American
289 Academy of Pediatrics, this is not a common standard practice.^{99,100} Nonetheless, screening is essential
290 for identifying children at risk of opioid exposure in the home.

291
292 For professionals that suspect patients have use / abuse issues, the Federal Drug Administration (FDA),
293 National Institute of Health (NIH), National Institute on Drug Abuse (NIDA), the American Dental
294 Association (ADA), and state prescription drug monitoring programs have resources available to review

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

295 the history of controlled substance prescriptions, as well as controlling the diversion of controlled
296 substances.^{101,102,103} Risk mitigation begins with understanding how to recognize drug seeking behavior.²
297 Screening patients prior to prescribing opioids should be standard practice.³⁰ Screening is commonly
298 performed with adult patients using a variety of screening tools.¹⁰⁴ Most agree some screening should be
299 done for adolescents, however there is no common standard.⁷⁷ Transparent discussion of medication use
300 with teens is important.¹⁰⁶

301

302 Recommendations

- 303 • Pain assessment should be considered for all patients.
- 304 • Minimize tissue damage and use careful technique when providing dental treatment.
- 305 • Achieve profound anesthesia prior to invasive treatment.
- 306 • Consider use of pre-emptive analgesia when postoperative pain is anticipated.
- 307 • Nonpharmacologic techniques (i.e. distraction) should be carefully considered as potentially
308 valuable interventions for pain management
- 309 • Use of APAP/NSAIDS as first line pharmacologic therapy for pain management.
- 310 • Use of opioids should be rare for pain management for pediatric dental patients.
- 311 • Screening of parent and patient is recommended when prescribing opioid analgesics.
- 312 • Proper disposal measures for all medications is recommended.
- 313 • Provider should be knowledgeable of risks associated with analgesic medications prescribed and
314 anticipate and manage adverse effects (asthma and NSAIDS, sedation and opioids, etc.)
- 315 • Consider seeking expert consultation for patients with chronic pain or other complicated pain
316 condition
- 317 • Providers should be familiar with analgesic properties of agents used during sedation or general
318 anesthesia
- 319 • Avoid prescribing opioid analgesics if patient is using benzodiazepines
- 320 • Synergistic effect from multiple medications (multi-modal analgesia) may be considered

321

322 References

- 323 1. International Association for the Study of Pain. Accessed: 2017-11-24. **(Archived by WebCite®**
324 **at <http://www.webcitation.org/6vDIQh5Vw>)**
- 325 2. Shaefer J, Barreveld AM, Arnstein P, Kulich RJ. Interprofessional education for the dentist in
326 managing acute and chronic pain. *Dental Clinics of North America* 2016; 825–42.

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

- 327 3. American Academy of Pediatrics, American Pain Society. The assessment and management of
328 acute pain in infants, children and adolescents. *Pediatrics* 2001;108(3):793-7.
- 329 4. Association of Paediatric Anaesthetists of Great Britain and Ireland. Good practice in
330 postoperative and procedural pain management, 2nd edition. *Paediatr Anaesth* 2012; 22(Suppl
331 1):1–79.
- 332 5. Pogatzki-Zahn EM., Zahn PK, Brennan TJ. Postoperative pain–clinical implications of basic
333 research. *Best practice & research clinical anaesthesiology* 2007; 21, 3-13.
- 334 6. Baccei ML, Fitzgerald M. Development of pain pathways and mechanisms. In Wall and
335 Melzack’s Textbook of Pain 6th ed. 2013.
- 336 7. Drew S. Best Practices for Management of Pain, Swelling, Nausea, and Vomiting in
337 Dentoalveolar Surgery. *Oral Maxillofacial Surg Clin N Am* 2015; 27: 393-404.
- 338 8. Brennan, TJ. Pathophysiology of postoperative pain. *Pain* 2011;152: S33.
- 339 9. Dostrovsky JO. Inflammatory and cancer-related orofacial pain mechanisms: insight from animal
340 models. *Orofacial Pain: Recent Advancements in Assessment, Management, and Understanding*
341 *of Mechanisms*. 2014.
- 342 10. Dawes MM, Andersson DA, Bennett DLH, Bevan S, McMahon SB. Inflammatory mediators and
343 modulators of pain. Wall and Melzack’s Textbook of Pain 6th ed. 2013.
- 344 11. Kaufman E, Epstein JB, Gorsky M, Jackson DL, Kadari A. Preemptive analgesia and local
345 anesthesia as a supplement to general anesthesia: a review, *Anesth Prog* 2005; 52: 29–38.
- 346 12. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central
347 neural plasticity. 2009; *J Pain* 10(9): 895–926.
- 348 13. Woolf CJ. Central sensitization: Implications for the diagnosis and treatment of pain. 2011; *PAIN*
349 152(3 Suppl): S2–15.
- 350 14. Stinson J, Connelly M, Kamper SJ. Models of care for addressing chronic musculoskeletal pain
351 and health in children and adolescents. *Best Practice & Research Clinical Rheumatology* 2016;
352 30: 468-82.
- 353 15. Buvanendran A, Lubenow TR, Krooni JS. Postoperative pain and its management. In Wall and
354 Melzack’s Textbook of Pain 6th ed. 2013.
- 355 16. Lee GY, Yamada J, Kyolo O, Shorkey A, Stevens B. Pediatric clinical practice guidelines for
356 acute procedural pain: a systematic review. *Pediatrics* 2014; 133(3): 500-15.
- 357 17. McGrath PJ, Unruh AM. Measurement and assessment of pediatric pain. Wall and Melzack’s
358 Textbook of Pain 6th ed. 2013.

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

- 359 18. Gouri AJ, Jaju RA, Tate A. The practice and perception of pain assessment in US pediatric
360 dentistry residency programs *Pediatric Dentistry*. 2010; 32(7) 546-50.
- 361 19. McGrath PJ, Walco GA, Turk DC, et al.. Core outcome domains and measures from Pediatric
362 Acute and Chronic/Recurrent Pain Clinical Trials: PedIMMPACT recommendations *The Journal*
363 *of Pain* 2008; 9(9): 771-83.
- 364 20. Hauer J, Jones BL Evaluation and management of pain in children. May 3 2017 Official reprint
365 from UpToDate www.uptodate.com.
- 366 21. Jain, A, Yeluri, R, Munshi, AK. Measurement and assessment of pain in children. *The Journal of*
367 *Clinical Pediatric Dentistry* 2012; 37(20):125-36.
- 368 22. American Academy of Pediatric Dentistry. Oral Health Policy on Acute Pediatric Dental Pain
369 Management. *Pediatr Dent* 2017; 39(6):99-101.
- 370 23. Kent ML, Tighe PJ, Belfer I et.al. The ACTION–APS–AAPM Pain Taxonomy (AAAPT)
371 multidimensional approach to classifying acute pain conditions. *The Journal of Pain* 2017; 18(5):
372 479-89.
- 373 24. Fillingim RB, Bruhl S, Dworkin RH, et al. The ACTION-American Pain Society Pain
374 Taxonomy (AAPT): An evidence-based and multidimensional approach to classifying chronic
375 pain conditions. *J Pain* 2014; 15:241-9.
- 376 25. Betsch TA, Gorodzinsky AY, Finley GA, Sangster M, Chorney J. What's in a name? health care
377 providers' perceptions of pediatric pain patients based on diagnostic labels. *Clinical Journal of*
378 *Pain* 2017; 38(8) 694-8.
- 379 26. Zeltzer LK, Krane EJ, Palermo TM. Pediatric Pain Management. *Nelson's Textbook of Pediatrics*
380 20th ed. 2016.
- 381 27. De Leeuw R, Klasser G. American Academy of Orofacial Pain: Guidelines for Assessment,
382 Diagnosis and Management. Quintessence Publishing 2013.
- 383 28. Batoz H, Semjen F, Bordes-Demolis M, Bénard A, Nouette-Gaulain K. Chronic postsurgical pain
384 in children: prevalence and risk factors. A prospective observational study. *Br J Anaesth* 2016;
385 117:489–96.
- 386 29. Palmero T, Eccleston C, Goldschneider K et. al. Assessment and management of children with
387 chronic pain: Position Statement from the American Pain Society. 2012.
- 388 30. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016 US Department
389 of Health and Human Services/Centers for Disease Control and Prevention.
- 390 31. Grégoire MC, Finley GR. Drugs for chronic pain in children: A commentary on clinical practice
391 and the absence of evidence. *Pain Res Management* 2013; 19(1): 47-50.

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

- 392 32. Sessel B. The societal, political, educational, scientific, and clinical context of orofacial pain.
393 Orofacial Pain: Recent Advancements in Assessment, Management, and Understanding of
394 Mechanisms. 2014.
- 395 33. American Academy of Pediatric Dentistry. Best Practices for Acquired Temporomandibular
396 Disorders in Infants, Children and Adolescents. 2017; 39(6): 354-60.
- 397 34. Kankkunen P, Vehviläinen-Julkunen K, Pietilä AM, Kokki H, Halonen P. Parents perception and
398 use of analgesic at home after day surgery. *Pediatr Anesthes* 2003; 13(2) 132-40.
- 399 35. Finley GA, Franck LS, Grunau RE, von Baeyer CL. Why children's pain matters. *Pain: Clinical*
400 *Updates* 2005;13(4):1-6.
- 401 36. Wong M, Copp PE, Haas DA. Postoperative pain in children after dentistry under general
402 anesthesia. *Anesth Prog* 2015; 62:140-52.
- 403 37. Chou, R, Gordon, DB, de Leon-Cassola, OA, et al. Guidelines on the management of
404 postoperative pain: a clinical practice guideline from the American Pain Society, American
405 Society of Regional Anesthesia and Pain Medicine, American Society of Anesthesiologists'
406 Committee on Regional Anesthesia, Executive Committee, and Administrative Counsel. *The*
407 *Journal of Pain* 2016; 17(2): 131-57.
- 408 38. Shirvani A, Shamszadeh S, Egbal MJ, Asgary S. The efficacy of non-narcotic analgesics on post-
409 operative endodontic pain: A systematic review and meta-analysis: The efficacy of non-steroidal
410 anti-inflammatory drugs and/or paracetamol on post-operative endodontic pain. *Jour of Oral*
411 *Rehab* 2017; 44(9):709-21.
- 412 39. Ashley PF, Parekh S, Moles DR, Anand P, MacDonald LC. Preoperative analgesics for additional
413 pain relief in children and adolescents having dental treatment. *Cochrane Database of Systematic*
414 *Reviews* 2016; Issue 8. Art. No.: CD008392.
- 415 40. Kaye AD, Helander EM, Vadivelu N, et al. Consensus statement for clinical pathway
416 development or perioperative pain management and pain transitions. *Pain Therapy* 2017 6(2):
417 129-41.
- 418 41. Boyce RA, Kirpalani T, Mohan N. Updates of topical and local anesthesia agents. *Dental Clinics*
419 *of North America* 2016; 60: 445-71.
- 420 42. Shavit I, Peri-Front Y, Rosen-Walther A, et al. A randomized trial to evaluate the effect of two
421 topical anesthetics on pain response during frenotomy in young infants. *Pain Med.* 2017;
422 18(2):356-62.

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

- 423 43. Glass JS, Hardy CL, Meeks NM, Carrol BT. Acute pain management in dermatology:risk
424 assessment and treatment. *Journal of the American Academy of Dermatology* 2015; 73(4): 543-
425 60.
- 426 44. Malamed SF, Tavana S, Falkel M. Faster onset and more comfortable injection with alkalinized
427 2% lidocaine with epinephrine 1:100,000. *Compend Contin Educ Dent* 2013; 34(1): 10-20.
- 428 45. Garret-Bernardin A, Cantile T, D'Antò V. Pain experience and behavior management inpediatric
429 dentistry: a comparison between traditional local anesthesia and the wand computerized delivery
430 system. *Pain Research and Management* 2017; Epub 2017 Feb 15: 1-6.
- 431 46. Shirvani A, Shamszadeh S, Engbal MJ, Marvasti LA, Asgary S. Effect of preoperative oral
432 analgesics on pulpal anesthesia in patients with irreversible pulpitis-a systematic review and
433 meta-analysis. *Clin Oral Investig.* 2017;21(1):43-52.
- 434 47. Baygin O, Tuzuner T, Isik B. Comparison of pre-emptive ibuprofen, paracetamol, and placebo
435 administration in reducing post-operative pain in primary tooth extraction. *International Journal*
436 *of Paediatric Dentistry* 2011; 21(4): 306-13.
- 437 48. Pacheco GS, Ferayorni A. Pediatric procedural sedation and analgesia. *Emerg Med Clin N Am*
438 2013; 31: 831-52.
- 439 49. American Academy of Pediatric Dentistry. Best practices on the use of nitrous oxide for pediatric
440 dental patients. *Pediatric Dentistry*; 39(6): 2017.
- 441 50. Laskarides, C. Update on analgesic medication for adult and pediatric dental patients *Dent Clin N*
442 *Am* 2016; 60: 347–66.
- 443 51. Conner ER, Musser ED, Colpitts KM, Laochamroonvorapongse DL, Koh JL. Perioperative
444 opioid administration in children with and without developmental delay undergoing outpatient
445 dental surgery. *Journal of Clinical Anesthesia* 2017; 37: 92-6.
- 446 52. Needleman HL, Harpayat S, Wu S, Allred EN, Berde C. Postoperative pain and other sequelae of
447 dental rehabilitations performed on children under general anesthesia. *Pediatr Dent* 2008;
448 30(2):111-21.
- 449 53. Keles S, Kocaturk O. Immediate postoperative pain and recovery time after pulpotomy performed
450 under general anaesthesia in young children pain. *Pain Research and Management* 2017; Epub
451 2017 Jun 8: 1-6.
- 452 54. Townsend JA, Ganzberg S, Thikkurissy S. The effect of local anesthetic on quality of recovery
453 characteristics following dental rehabilitation under general anesthesia in children. *Anesth Prog.*
454 2009; 56(4): 115-22.

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

- 455 55. American Academy of Pediatric Dentistry Best practices on the use of local anesthesia for pediatric
456 dental patients. *Pediatr Dent* 2017; 39(6): 266-272.
- 457 56. Parekh S, Gardener C, Ashley PF, Walsh T. Does local anesthetic injection in children and young
458 people having general anesthesia reduce pain after treatment? *Cochrane Database of Systematic*
459 *Reviews* 2014; Issue 12 No.:CD009742.
- 460 57. Landier WN, Tse A. Use of complementary and alternative medical interventions for the
461 management of procedure-related pain, anxiety, and distress in pediatric oncology: an integrative
462 review. *J of Pediatr Nursing*. 2010; 25: 566-79.
- 463 58. Fein A, Zempsky WT, Cravero JP. Relief of pain and anxiety in pediatric patient in emergency
464 medical systems. *Pediatrics* 2012;130(5):1391-1405.
- 465 59. Lewin D, Dahl R. Importance of sleep in the management of pediatric pain. *Journal of*
466 *Developmental & Behavioral Pediatrics* 1999;20(4):244-52.
- 467 60. Ruest S, Anderson A. Management of acute pediatric pain in the emergency department. *Curr*
468 *Opin Pediatr* 2016;28(3): 298-304.
- 469 61. Sinha M, Christopher NC, Fenn R, Reeves L. Evaluation of nonpharmacologic methods of pain
470 and anxiety management for laceration repair in the pediatric emergency department. *Pediatrics*
471 2006;117(4):1162-1168.
- 472 62. Rabbitts J, Fisher E, Rosenbloom BN. Prevalence and Predictors of Chronic Postsurgical Pain in
473 Children: A Systematic Review and Meta-Analysis. *The Journal of Pain* 2017; 18(6); 605-14.
- 474 63. Lyons RA, Understanding basic behavioral support techniques as an alternative to sedation and
475 anesthesia. *Special Care Dentistry* 2009; 29(1): 39-50.
- 476 64. Uman LS, Chambers CT, McGrath PJ, et al. Psychological interventions for needle-related
477 procedural pain and distress in children and adolescents. *Cochrane Database Systematic Reviews*
478 2007; Issue. 3 Art. No. CD005179.
- 479 65. Goettems ML, Zborowski EJ, Costa FC, et al. Nonpharmacologic intervention on the prevention
480 of pain and anxiety during pediatric dental care: a systematic review. *Academic Pediatrics*. 2017;
481 17(2): 110-19.
- 482 66. Uman LS, Birnie KA, Noel M, et al. Psychological interventions for needle-related procedural
483 pain and distress in children and adolescents. *Cochrane Database Systematic Reviews* 2013; Issue
484 Art. No.: CD005179.
- 485 67. Davidson F, Snow S, Haydenc J, Chorney J Psychological interventions in managing
486 postoperative pain in children: a systematic review *PAIN* 2016; 157: 1872-86.

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

- 487 68. Bukola IM, Paula D, The effectiveness of distraction as procedural pain management technique in
488 paediatric oncology patients: a meta-analysis and systematic review. *Journal of Pain and*
489 *Symptom Management* 2017; 54(4): 589-600.
- 490 69. Ramirez-Carrasco A, Butron-Tellez GironC, Sanchez-Armass O, Pierdant-Perez M. Effectiveness
491 of hypnosis in combination with conventional techniques of behavior management in
492 anxiety/pain reduction during dental anesthetic infiltration. *Pain Res Manag* 2017; Epub 2017
493 Apr 1: 1-5.
- 494 70. Eccleston C, Palmero TM, Williams ACDC et al. Psychological therapies for the management of
495 chronic and recurrent pain in children and adolescents. *Cochrane Database of Systematic*
496 *Reviews* 2014; Issue 5 Art. No.: CD003968.
- 497 71. Brown ML, Rojas E, Gouda S. A mind–body approach to pediatric pain management, *Children*
498 2017; 4, E50.
- 499 72. Munshi AK, Hegde AM, Girdhar D. Clinical evaluation of electronic dental anesthesia for
500 various procedures in pediatric dentistry. *J Clin Pediatr Dent.* 2000;24:199-204.
- 501 73. Kasat V, Gupta A, Ladd R, Kathariya M, Saluja H, Farooqui AA. Transcutaneous electric nerve
502 stimulation(TENS) in dentistry- A review. *J Clin Exp Dent.* 2014;6(5):562-568
- 503 74. Aminabadi NA, Farahani RMZ, Balayi GE. The efficacy of distraction and counterstimulation in
504 the reduction of pain reaction to intraoral injection by pediatric patients. *J Contemp Dent Pract*
505 2008; 9: 33-40.
- 506 75. Klassen JA, Liang Y, Tjosvold L, et al. Music for pain and anxiety in children undergoing
507 medical procedures: a systematic review of randomized controlled trials. *Ambul Pediatr.*
508 2008;8:117-28.
- 509 76. Hartling L, Ali S, Dryden DM et al. How safe Are common analgesics for the treatment of acute
510 pain for children? a systematic review. *Pain Research and Management* 2016; Article ID
511 5346819, 1-15.
- 512 77. Walco GA, Jennifer NG, Phillips J et al Opioid Analgesics Administered for Pain in the Inpatient
513 Pediatric Setting. *The Journal of Pain* 2017;18(10): 1270-1276.
- 514 78. Kokki H. Nonsteroidal anti-inflammatory drugs for postoperative pain: a focus on children.
515 *Pediatr Drugs* 2003;5(2): 102-23.
- 516 79. Neri E, Maestro A, Minen F, et al. Sublingual ketorolac versus sublingual tramadol for moderate
517 to severe post-traumatic bone pain in children: a double-blind, randomized, controlled trial *Arch*
518 *Dis Child* 2013; 98:721-24.

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

- 519 80. Shah R, Sawardekar A, Suresh A, Pediatric Acute Pain Management. In Practical Management of
520 Pain: 5th ed. Elsevier Inc: 304-311.
- 521 81. Becker DE. Pain management: part 1: Managing acute and postoperative dental pain. Anesth
522 Prog 2010;57(2):67-79.
- 523 82. Ong CK, Seymour RA, Lirk P, et al. Combining paracetamol (acetaminophen) with nonsteroidal
524 anti-inflammatory drugs: a qualitative systematic review of analgesic efficacy for acute
525 postoperative pain. Anesth Analg. 2010; 110(4):1170-9.
- 526 83. Schechter JL, Waldo GA. The potential impact on children of the CDC guidelines for prescribing
527 opioids for chronic pain: above all, do no harm. Pediatrics 2016 170(5) 425-426.
- 528 84. Cooper TE, Wiffen PJ, Heathcote LC et al. Antiepileptic drugs for chronic non-cancer pain in
529 children and adolescents. Cochrane Database of Systematic Reviews 2017; Issue 8. Art. No.:
530 CD012536.
- 531 85. Fortuna RJ, Robbins BW, Cajola E et al. Prescribing of controlled medications to adolescents and
532 young adults in the United States. Pediatrics. 2010; 126(6): 1108-1116.
- 533 86. Van Cleve, WC, Grigg EB Variability in opioid prescribing for children undergoing ambulatory
534 surgery in the United States. Journal of Clinical Anesthesia 2017; 41:16–20.
- 535 87. Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths –
536 United States, 2010-2015. Morb Mortal Wkly Rep. 2016;65(5051):1445-1452.
- 537 88. Food and Drug Administration Drug Safety Communication: FDA restricts use of prescription
538 codeine pain and cough medicines and tramadol pain medicines in children; recommends against
539 use in breastfeeding women. Accessed: 2018-02-25. (Archived by WebCite® at
540 <http://www.webcitation.org/6xVGnS3vO>)
- 541 89. European Medicines Agencies Position on Codeine. Coordination Group for Mutual Recognition
542 and Decentralised Procedures. Accessed: 2018-02-25. (Archived by WebCite® at
543 <http://www.webcitation.org/6xVFwOyz8>)
- 544 90. Schnabel A, Reichl SU, Meyer-Frießem C, Zahn PK, Pogatzki-Zahn E. Tramadol for
545 postoperative pain treatment in children. Cochrane Database Systematic Review 2015; Issue 3
546 Art No.:CD009574.
- 547 91. Dancel R, Liles EA, Fiore D. 2017; Acute pain management in hospitalized children. Rev Recent
548 Clin Trials. 12(4): 277-83.
- 549 92. US Department of Health and Human Services Center for Disease Control and Prevention.
550 Document on calculating total daily dose of opioids for safer dosage. Accessed: 2018-02-25.
551 (Archived by WebCite® at <http://www.webcitation.org/6xV2QBafv>)

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

- 552 93. Tompkins Providing chronic pain management in the 5th vital sign era: historical and treatment
553 perspectives in a modern day medical dilemma. *Drug and alcohol dependence* 2017; 173: S11-21.
- 554 94. Shueb SS, Nixdorf DR, John MT, Alonso BF, Durham J. What is the impact of acute and chronic
555 orofacial pain on quality of life? *Journal of Dentistry* 2015; 43: 1203-1210.
- 556 95. DePhillips M, Watts J, Lowry J, Dowy MD. Opioid prescribing practices in pediatric acute care
557 settings. *Pediatric Emergency Care* 2017: Epub ahead of print. 1-6.
- 558 96. Allareddy V, Rampa S, Allareddy V. Opioid abuse in children: an emerging public health crisis in
559 the United States! *Pediatric Research* 2017; 82 (4): 562-3.
- 560 97. McCabe SE, West BT, Veliz P, et al. Trends in medical and nonmedical use of prescription
561 opioids among US adolescents: 1976–2015. *Pediatrics* 2017; 139(4): 1-9.
- 562 98. Bagley SM, Hadland SE, Carney BL, Saitz R. Addressing stigma in medication treatment of
563 adolescents with opioid use disorder. *Journal of Addiction Medicine* 2017; 11(6) 415-6.
- 564 99. Spehr MK, Coddington J, Azza H, Jones E. Parental opioid abuse: barriers to care, policy, and
565 implications for primary care pediatric providers. *Jour Pediatr Healthcare*; 6 695-702..
- 566 100. Lane WG, Dubowitz H, Feigelman S, et al. Screening for parental substance abuse in pediatric
567 primary care. *Ambulatory Pediatrics* 2007; 7: 458-62.
- 568 101. National Institute of Health. National Institute on Drug Abuse. URL:<https://www.drugabuse.gov/>.
569 Accessed: 2018-02-25. (Archived by WebCite® at <http://www.webcitation.org/6xV4BfzAb>)
- 570 102. O’Neil M. *The ADA Practical Guide to Substance Use Disorders and Safe Prescribing*. Wiley
571 Blackwell 2015.
- 572 103. US Dept of Health and Human Services. About the opioid epidemic.
573 <https://www.hhs.gov/opioids/about-the-epidemic/>. Accessed 2018-03-02. (Archived by
574 WebCite® at <http://www.webcitation.org/6xc3REvBU>).
- 575 104. Smith SM, Paillard F, McKeown A, Instruments to identify prescription medication misuse,
576 abuse, and related events in clinical trials: an ACTION systematic review. *The Journal of Pain*
577 2015; 16(5): 389-411.
- 578 105. American Academy of Pediatrics Committee on Psychosocial Aspects of Child and Family
579 Health and American Pain Society Task Force on Pain in Infants, Children, and Adolescents. *The*
580 *Assessment and Management of Acute Pain in Infants, Children, and Adolescents*. *Pediatrics*
581 2001;108(3): 793-797.
- 582 106. American Academy of Pediatric Dentistry Policy on Substance Abuse in Adolescent Patients. *Pediatr*
583 *Dent* 2017; 39(6): 77-80.
- 584